Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 804 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $82.64, for a total value of $66,442.56. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,489,335.36. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total value of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Performance

IRON stock opened at $78.84 on Friday. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The stock’s 50 day simple moving average is $74.60 and its 200 day simple moving average is $69.96. The firm has a market cap of $301.96 million, a P/E ratio of -11.98 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. As a group, equities research analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IRON. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley lifted their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, HC Wainwright lifted their price target on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Disc Medicine in the second quarter worth about $180,502,000. JPMorgan Chase & Co. raised its position in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after buying an additional 828,248 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Disc Medicine during the 4th quarter worth about $51,616,000. Jennison Associates LLC acquired a new stake in shares of Disc Medicine in the 4th quarter worth approximately $42,252,000. Finally, Perceptive Advisors LLC bought a new position in shares of Disc Medicine in the fourth quarter valued at approximately $35,794,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.